BioStock: ClearPoint Neuro delivers first order to CLS

Following the FDA clearance of Clinical Laserthermia Systems’ MR-guided laser ablation system in neurosurgery, US commercialisation was swiftly initiated. The commercialisation is led by the medtech’s global distributor ClearPoint Neuro. On Monday, CLS could announce that their efforts have already paid off in the form of a first order worth 5,5 million SEK. BioStock reached out to CLS’ CEO Dan Mogren for a comment.

Read the article at biostock.se:

https://www.biostock.se/en/2022/10/clearpoint-neuro-delivers-first-order-to-cls/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/